Lyra Therapeutics (NASDAQ:LYRA) Lowered to Neutral at HC Wainwright
HC Wainwright lowered shares of Lyra Therapeutics (NASDAQ:LYRA – Free Report) from a buy rating to a neutral rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has $2.00 target price on the stock, down from their previous target price of $12.00. A number of other research analysts […]
More Stories
Major US Cities on Alert After US Airstrikes on Iranian Nuclear Facilities
By Jack Phillips Three major U.S. cities indicated that they’re on heightened alert following U.S. military airstrikes targeting Iranian nuclear...
Envestnet Portfolio Solutions Inc. Has $3.89 Million Position in Citigroup Inc. (NYSE:C)
Envestnet Portfolio Solutions Inc. cut its holdings in Citigroup Inc. (NYSE:C – Free Report) by 26.1% in the 1st quarter,...
Schwab US Large-Cap ETF (NYSEARCA:SCHX) Shares Sold by Kingswood Wealth Advisors LLC
Kingswood Wealth Advisors LLC cut its holdings in shares of Schwab US Large-Cap ETF (NYSEARCA:SCHX – Free Report) by 22.2%...
Blue Trust Inc. Raises Stock Holdings in Boston Scientific Corporation (NYSE:BSX)
Blue Trust Inc. boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 13.0% during the...
Johnson Investment Counsel Inc. Has $936,000 Holdings in Welltower Inc. (NYSE:WELL)
Johnson Investment Counsel Inc. lessened its stake in Welltower Inc. (NYSE:WELL – Free Report) by 15.9% in the 1st quarter,...
Blue Trust Inc. Buys 434 Shares of General Dynamics Corporation (NYSE:GD)
Blue Trust Inc. increased its position in shares of General Dynamics Corporation (NYSE:GD – Free Report) by 26.8% during the...